DE10065413A1 - Dentifrice - Google Patents
DentifriceInfo
- Publication number
- DE10065413A1 DE10065413A1 DE2000165413 DE10065413A DE10065413A1 DE 10065413 A1 DE10065413 A1 DE 10065413A1 DE 2000165413 DE2000165413 DE 2000165413 DE 10065413 A DE10065413 A DE 10065413A DE 10065413 A1 DE10065413 A1 DE 10065413A1
- Authority
- DE
- Germany
- Prior art keywords
- dental care
- coenzyme
- product according
- care product
- ubiquinone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000551 dentifrice Substances 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 150000003669 ubiquinones Chemical class 0.000 claims abstract description 13
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 9
- 230000003449 preventive effect Effects 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 9
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 51
- 230000003239 periodontal effect Effects 0.000 claims description 13
- 229940112822 chewing gum Drugs 0.000 claims description 12
- 235000015218 chewing gum Nutrition 0.000 claims description 12
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 12
- 239000000606 toothpaste Substances 0.000 claims description 11
- 239000003765 sweetening agent Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 229940034610 toothpaste Drugs 0.000 claims description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 150000002222 fluorine compounds Chemical class 0.000 claims description 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 4
- 229940035936 ubiquinone Drugs 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000002285 corn oil Substances 0.000 claims description 3
- 235000005687 corn oil Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 235000021092 sugar substitutes Nutrition 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 230000000675 anti-caries Effects 0.000 claims 1
- 239000012459 cleaning agent Substances 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 7
- 230000002715 bioenergetic effect Effects 0.000 description 6
- 210000004195 gingiva Anatomy 0.000 description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- -1 PEG-40 Substances 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000001055 chewing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000011687 Electron Transport Complex II Human genes 0.000 description 2
- 108010076322 Electron Transport Complex II Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 210000004261 periodontium Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000003319 supportive effect Effects 0.000 description 2
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical class O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 description 1
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- 239000004377 Alitame Chemical class 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- GLWQRIMWMLJRIB-UHFFFAOYSA-N F.F.CCO Chemical compound F.F.CCO GLWQRIMWMLJRIB-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 229920001908 Hydrogenated starch hydrolysate Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical class CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 229960005164 acesulfame Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000019409 alitame Nutrition 0.000 description 1
- 108010009985 alitame Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003090 carboxymethyl hydroxyethyl cellulose Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229960003082 galactose Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000011256 inorganic filler Substances 0.000 description 1
- 229910003475 inorganic filler Inorganic materials 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000001527 leucocytic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229910001562 pearlite Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000008262 pumice Substances 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical class OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G4/00—Chewing gum
- A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
Abstract
Die Erfindung betrifft ein Zahnpflegemittel, enthaltend Ubichinon-Derivate zur therapeutischen und/oder präventiven Behandlung entzündlicher und degenerativer Erkrankungen des Zahnfleisches und des Zahnhalteapparates.The invention relates to a dentifrice containing ubiquinone derivatives for the therapeutic and / or preventive treatment of inflammatory and degenerative diseases of the gums and the tooth-holding apparatus.
Description
Die Erfindung betrifft ein Zahnpflegemittel enthaltend Ubichinon-Derivate zur therapeutischen und/oder präventiven Behandlung entzündlicher und degenerativer Erkrankungen des Zahnfleisches und des Zahnhalteapparates.The invention relates to a dentifrice containing ubiquinone derivatives for therapeutic and / or preventive treatment of inflammatory and degenerative diseases of the gums and the Periodontal apparatus.
Der Begriff "Ubichinon-Derivate" umfasst solche Verbindungen, die ein p-
Benzochinon-Strukturelement aufweisen, vorzugsweise solche der
allgemeinen Formel (I),
The term “ubiquinone derivatives” encompasses those compounds which have a p-benzoquinone structural element, preferably those of the general formula (I),
worin n eine ganze Zahl von 1 bis 13, insbesondere 5 bis 11 bedeutet. Gegebenenfalls können auch Gemische verschiedener Ubichinon-Derivate zum Einsatz kommen. Besonders bevorzugt ist 2,3-Dimethoxy-5-methyl-6- decaprenyl-1,4-benzochinon also Coenzym Q10 (n = 10, Ubichinon).wherein n is an integer from 1 to 13, in particular 5 to 11. If necessary, mixtures of various ubiquinone derivatives can also be used. 2,3-Dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone, ie coenzyme Q 10 (n = 10, ubiquinone), is particularly preferred.
Durch Oxidation oder Reduktion können der Hydrochinon- und Chinon- Anteil der Substanz ineinander übergehen. Bei der Oxidation ist durch Verlust von 2π-Elektronen der aromatische Charakter aufgehoben, wobei die beiden verbliebenen Doppelbindungen fixiert sind. Chinon bildet zusammen mit dem Hydrochinon ein Redoxsystem, dessen Potential von der Wasserstoffionen-Konzentration und vom Verhältnis der Konzentrationen beider Komponenten abhängig ist. By oxidation or reduction, the hydroquinone and quinone Merging the proportion of the substance. When oxidation is through Loss of 2π electrons canceled the aromatic character, whereby the two remaining double bonds are fixed. Quinone forms together with the hydroquinone a redox system, the potential of the hydrogen ion concentration and the ratio of Concentrations of both components is dependent.
Coenzym Q10 ist eine gelb-orange kristalline Substanz mit einem Schmelzpunkt von 49 ± 1°C. Sie lässt sich so gut wie nicht in Wasser und Methanol lösen, ist aber etwas löslich in Ethanol, mittelmäßig löslich in Fetten, wie Maisöl und Sojaöl, und sehr gut löslich in Aceton, Ether, Chloroform, Hexan und Benzol. Coenzym Q10 ist bei Zimmertemperatur für mindestens 3 Jahre beständig, aber nicht besonders gut haltbar bei direkter Sonneneinstrahlung. Coenzym Q10 ähnelt einem Lipid und kann als eine fettlösliche Substanz mit Vitamin-Charakter angesehen werden.Coenzyme Q 10 is a yellow-orange crystalline substance with a melting point of 49 ± 1 ° C. It is practically impossible to dissolve in water and methanol, but is somewhat soluble in ethanol, moderately soluble in fats such as corn oil and soybean oil, and very soluble in acetone, ether, chloroform, hexane and benzene. Coenzyme Q 10 is stable at room temperature for at least 3 years, but is not particularly durable in direct sunlight. Coenzyme Q 10 is similar to a lipid and can be regarded as a fat-soluble substance with a vitamin character.
Durch sein Redox-Potential besitzt Coenzym Q10 antioxidative Eigenschaften. Dadurch wirkt es reaktiven Sauerstoff-Spezies und freien Sauerstoff-Radikalen entgegen, die in den Geweben des Körpers vorrangig bei ischämischen und entzündlichen Veränderungen auftreten. Auf diese Weise kann Coenzym Q10, insbesondere bei lokaler Applikation, einen antiphlogistischen Effekt ausüben und das Gewebe vor entzündlichen und ischämischen Einflüssen schützen.Due to its redox potential, Coenzyme Q 10 has antioxidative properties. It counteracts reactive oxygen species and free oxygen radicals, which occur primarily in the tissues of the body with ischemic and inflammatory changes. In this way, coenzyme Q 10 can have an anti-inflammatory effect, especially when applied locally, and protect the tissue against inflammatory and ischemic influences.
Die Bioverfügbarkeit von Coenzym Q10 ist aufgrund der mangelhaften Resorption gering. Die in das Plasma aufgenommene Menge wird relativ schnell in den Ubichinon Pool der Leber überführt. Daher erscheinen optimale therapeutische Erfolge überwiegend mit einer lokalen Applikation erreichbar.The bioavailability of coenzyme Q 10 is low due to the poor absorption. The amount absorbed into the plasma is transferred to the ubiquinone pool of the liver relatively quickly. Therefore, optimal therapeutic success appears to be predominantly achievable with a local application.
Tierexperimentell Untersuchungen von Matsumoto aus dem Jahre 1969 zeigten, dass eine Verabreichung von Coenzym Q10 einen günstigen Effekt auf periodontale Läsionen der Ratte hatte (z. B. Matsumura T., Kimata M., Tsunemitsu A., Akiyoshi M., Effect of Coenzyme Q on blood-citrate and calcium levels and on the periodontium of citrated rats, J. Dent. Res. 1969; 48 (6): 1264-1267 oder Matsumura T., Kimata M., Tsunemitsu A., Akiyoshi M., Effect of Coenzyme Q administration on the periodontal lesions in citrated rats, Koku-Eisei. Gakkai. Zasshi. 1969; 19 (2): 134-142). In Übereinstimmung damit stellten Hsieh et al. 1983 fest, dass in der entzündeten Gingiva des Hundes die Coenzym Q10-abhängigen Enzymaktivitäten Veränderungen unterliegen.Animal studies from Matsumoto in 1969 showed that administration of coenzyme Q 10 had a beneficial effect on periodontal lesions in the rat (e.g. Matsumura T., Kimata M., Tsunemitsu A., Akiyoshi M., Effect of Coenzyme Q on blood-citrate and calcium levels and on the periodontium of citrated rats, J. Dent. Res. 1969; 48 (6): 1264-1267 or Matsumura T., Kimata M., Tsunemitsu A., Akiyoshi M., Effect of Coenzyme Q administration on the periodontal lesions in citrated rats, Koku-Eisei. Gakkai. Zasshi. 1969; 19 (2): 134-142). In accordance with this, Hsieh et al. 1983 found that in the inflamed gingiva of the dog, the coenzyme Q 10 -dependent enzyme activities are subject to changes.
Auf der Basis dieser Befunde wurden seit Beginn der 70er Jahre auch Untersuchungen an Menschen durchgeführt. Dabei wurde nachgewiesen, dass eine Verabreichung von Coenzym Q10 periodontale Erkrankungen günstig beeinflusst (Tsunemitsu A., Matsumura T., Effects of Coenzyme Q administration an hypercitricemia of patients Q with periodontal disease, J. Dent. Res. 1967; 46 (6): 1382-1384). Bei diesen Fällen wurde auch ein Mangel an Coenzym Q10 im Gewebe aus Gingiva bei Patienten mit Periodontal-Erkrankung festgestellt (z. B. Littarru G. P., Nakamura R., Ho L., Folkers K., Kuzell W. C., Deficiency of Coenzyme Q10 in gingival tissue from patients with periodontal disease, Proc. Natl. Acad. Sci. U.S.A. 1971; 68 (10): 2332-2335). Daraus resultierte eine verstärkte Behandlung dieser Erkrankungen mit Coenzym Q10 (Matsumura T., Saji S., Nakamura R., Folkers K., Evidence for enhanced treatment of periodontal disease by therapy with Coenzyme Q, Int. J. Vitam. Nutr. Res. 1973; 43 (4): 537-548).Based on these findings, studies on humans have also been carried out since the early 1970s. It was demonstrated that the administration of coenzyme Q 10 has a beneficial effect on periodontal diseases (Tsunemitsu A., Matsumura T., Effects of Coenzyme Q administration an hypercitricemia of patients Q with periodontal disease, J. Dent. Res. 1967; 46 (6) : 1382-1384). In these cases, a deficiency of coenzyme Q 10 in the tissue from gingiva was also found in patients with periodontal disease (e.g. Littarru GP, Nakamura R., Ho L., Folkers K., Kuzell WC, Deficiency of Coenzyme Q 10 in gingival tissue from patients with periodontal disease, Proc. Natl. Acad. Sci. USA 1971; 68 (10): 2332-2335). This resulted in an increased treatment of these diseases with coenzyme Q 10 (Matsumura T., Saji S., Nakamura R., Folkers K., Evidence for enhanced treatment of periodontal disease by therapy with Coenzyme Q, Int. J. Vitam. Nutr. Res 1973; 43 (4): 537-548).
1975 beschrieben Iwamoto et al. (Iwamoto Y., Nakamura R., Folkers K., Morrison R. F., Study of periodontal disease and Coenzyme Q, Res. Commu. Chem. Pathol. Pharmacol. 1975; 11 (2): 265-271) die Behandlung eines Patienten mit einer schweren, chronischen Parodontal- Erkrankung. In diesem Fall ergab eine langfristige Behandlung mit Coenzm Q10 nach 7-8 Wochen eine signifikante Verbesserung mehrerer Parameter. Im gleichen Jahr wurde die unterstützende Behandlung einer Paraodontal-Erkrankung mit Coenzym Q10 zur Verbesserung der Bioenergetik an 8 Patienten durchgeführt. Unter der Behandlung verbesserte sich die Erkrankung. Die Tiefe der Parodontaltaschen nahm ab. Gleichzeitig nahm die Aktivität der Succinat-Ubichinon-Reduktase zu, was mit dem Heileffekt in Verbindung stehen könnte (Wikinson E. G., Arnold R. M., Folkers K., Hansen I., Kishi H., Bioenergetics in clinical medicine. II. Adjunctive treatment with Coenzyme Q in periodontal therapy, Res. Commun. Chem. Pathol. Pharmacol. 1975; 12 (1): 111-123). Die spezifische Aktivität der Succinat-Ubichinon-Reduktase wurde von Hansen et al. (Hansen I. L., Iwamoto Y., Kishi T., Folkers K., Thompson I. L., Bioenergetics in clinical medicine. IX. Gingival and leucocytic deficiencies of Coenzyme Q10 in patients with periodontal disease, Res. Commun. Chem. Pathol. Pharmacol. 1976; 14 (4): 729-738) untersucht. In diese Studie wurden 29 Patienten mit schwerer Parodontal-Erkrankung und einem auf 20-63% abgefallenen Coenzym Q10-haltigen Enzym in der Gingiva einbezogen. Das zeigte, dass derartige Patienten häufig einen Mangel an Coenzym Q10 in der Gingiva und in den Leukozyten aufweisen, woraus ein gestörtes Gleichgewicht in der Bioenergetik resultiert. Auch diese Untersuchungen unterstützten den supportiven Charakter von Coenzym Q10 bei Erkrankungen der Gingiva und des Periodontiums.In 1975 Iwamoto et al. (Iwamoto Y., Nakamura R., Folkers K., Morrison RF, Study of periodontal disease and Coenzyme Q, Res. Commu. Chem. Pathol. Pharmacol. 1975; 11 (2): 265-271) treated a patient with a severe, chronic periodontal disease. In this case, long-term treatment with Coenzm Q 10 after 7-8 weeks resulted in a significant improvement in several parameters. In the same year, supportive treatment of a periodontal disease with coenzyme Q 10 to improve bioenergetics was carried out on 8 patients. The disease improved during treatment. The depth of the periodontal pockets decreased. At the same time, the activity of succinate ubiquinone reductase increased, which could be related to the healing effect (Wikinson EG, Arnold RM, Folkers K., Hansen I., Kishi H., Bioenergetics in clinical medicine. II. Adjunctive treatment with Coenzyme Q in periodontal therapy, Res. Commun. Chem. Pathol. Pharmacol. 1975; 12 (1): 111-123). The specific activity of the succinate ubiquinone reductase was described by Hansen et al. (Hansen IL, Iwamoto Y., Kishi T., Folkers K., Thompson IL, Bioenergetics in clinical medicine. IX. Gingival and leucocytic deficiencies of Coenzyme Q 10 in patients with periodontal disease, Res. Commun. Chem. Pathol. Pharmacol. 1976; 14 (4): 729-738). This study included 29 patients with severe periodontal disease and an enzyme in the gingiva that had fallen to 20-63% coenzyme Q 10 . This showed that such patients often have a lack of coenzyme Q 10 in the gingiva and leukocytes, which results in a disturbed balance in bioenergetics. These studies also support the supportive nature of coenzyme Q 10 in diseases of the gingiva and periodontium.
Wilkinson et al. (Res. Commun. Chem. Pathol. Pharmacol., loc. cit.) untersuchten 18 Patienten mit einem ähnlichen Krankheitsbild. Anhand der Tiefe der Zahntaschen und anderer Parameter wurde ein positiver Effekt von Coenzym Q10 nachgewiesen.Wilkinson et al. (Res. Commun. Chem. Pathol. Pharmacol., Loc. Cit.) Examined 18 patients with a similar clinical picture. Based on the depth of the tooth pockets and other parameters, a positive effect of Coenzyme Q 10 was proven.
Folkers und Watanabe (Folkers K., Watanabe T., Bioenergetics in clinical medicine-X. Survey of the adjunctive use of Coenzyme Q with oral therapy in treating periodontal disease, J. Med. 1977; 8 (5): 333-348) gingen davon aus, dass 60-80% der Amerikaner jüngeren und mittleren Alters an Parodontal-Erkrankungen leiden. Dabei schlugen die Autoren vor, neben der äußerlichen Pflege auch eine Verbesserung der Ernährung und der Bioenergetik durch Coenzym Q10 durchzuführen. Untersuchungen von Hori bestätigten diese Annahme. Hanioka et al. (Hanioka T., Tanaka M., Ojima M., Shizukuishi S., Folkers K., Effects of topical application of Coenzyme Q10 on adult periodontitis, Mol. Aspects Med. 1994; 15 Suppl: s241-s248) führten an 10 erwachsenen männlichen Patienten eine topische Applikation von Coenzym Q10 durch. Ihre Ergebnisse zeigten, dass die Substanz bei Erwachsenen allein und in Kombination das Krankheitsbild nachweislich besserte. Es wurde ein signifikanter Rückgang der gingivalen und parodontalen Veränderungen gefunden.Folkers and Watanabe (Folkers K., Watanabe T., Bioenergetics in clinical medicine-X. Survey of the adjunctive use of Coenzyme Q with oral therapy in treating periodontal disease, J. Med. 1977; 8 (5): 333-348) assumed that 60-80% of younger and middle-aged Americans suffer from periodontal disease. The authors suggested that in addition to external care, the diet and bioenergetics should also be improved with coenzyme Q 10 . Investigations by Hori confirmed this assumption. Hanioka et al. (Hanioka T., Tanaka M., Ojima M., Shizukuishi S., Folkers K., Effects of topical application of Coenzyme Q 10 on adult periodontitis, Mol. Aspects Med. 1994; 15 Suppl: s241-s248) led to 10 adult male patients by topical application of coenzyme Q 10 . Their results showed that the substance was shown to improve the clinical picture in adults alone and in combination. A significant decrease in gingival and periodontal changes was found.
Als praktischer Zahnarzt teilte Larsen (Larsen P. E. M., Coenzyme Q10- Substitution bei der Behandlung von Parodontose. Erfahrung aus der Praxis, J. f. Orthomolekulare Medizin 1996; 2 (4): 150-152) mit, dass die Substitution mit Coenzym Q10 bei der Behandlung von Parodontose eine wertvolle Unterstützung der konventionellen Parodontose-Behandlung darstellt. In Übereinstimmung damit vertraten schwedische Zahnärzte (Schunke H., Parodontopathien-Supplementation mit Coenzym Q10, Initiative Ernährung 2000) die Meinung, dass eine lokale Anwendung von Coenzym Q10 die Entzündungsrate reduziert und die Bildung von Zahnfleischtaschen hemmt. Gleichzeitig ließ sich auch die Blutungsneigung einschränken. Der therapeutische Nutzen von Coenzym Q10 wurde 1994 auch von Nylander bestätigt. In seinen Untersuchungen wurden 6 Patienten behandelt, die parodontale Krankheiten verschiedenen Schweregrades aufwiesen. Unter Berücksichtigung der Zahntaschen und der Blutung, zeigte sich eine Verbesserung dieser Parameter unter Verabreichung von Coenzym Q10 (Nylander M., Coenzme Q10: A therapeutic adjuvant in periodontal disease, 9th Internatl. Symp. on Biomed. and Clin. Asp. of Coenzyme Q; Ancona, 1996; 41; (Abstract)).As a practical dentist, Larsen (Larsen PEM, Coenzyme Q 10 - Substitution in the treatment of periodontitis. Experience from practice, J. f. Orthomolecular Medicine 1996; 2 (4): 150-152) announced that the substitution with Coenzyme Q 10 is a valuable support for conventional periodontal treatment in the treatment of periodontitis. In line with this, Swedish dentists (Schunke H., periodontopathy supplementation with coenzyme Q 10 , initiative Nutrition 2000) were of the opinion that local use of coenzyme Q 10 reduces the rate of inflammation and inhibits the formation of gum pockets. At the same time, the tendency to bleed could be restricted. The therapeutic benefit of coenzyme Q 10 was also confirmed in 1994 by Nylander. In his studies, 6 patients were treated who had periodontal diseases of various degrees of severity. Taking into account the tooth pockets and the bleeding, there was an improvement in these parameters when coenzyme Q 10 was administered (Nylander M., Coenzme Q 10 : A therapeutic adjuvant in periodontal disease, 9th International Symp. On Biomed. And Clin. Asp. Of Coenzyme Q; Ancona, 1996; 41; (abstract)).
Auch Lister (Lister R. E., Coenzyme Q10 and periodontal disease (letter), Br. Dent. J. 1995; 179 (6): 200-201) fand bei der Parodontal-Erkrankung einen günstigen Effekt. Lister (Lister RE, Coenzyme Q 10 and periodontal disease (letter), Br. Dent. J. 1995; 179 (6): 200-201) also found a beneficial effect on periodontal disease.
1995 wurden die vorhandenen Befunde von Watts übersichtlich zusammengestellt. Allerdings reichten nach den Autoren die Befunde für eine endgültige Aussage zu einer erfolgreichen Anwendung der Substanz nicht aus (Watts T. L., Coenzyme Q10 and periodontal treatment: Is there any beneficial effect? Br. Dent. J. 1995; 178 (6): 209-213).In 1995 Watts' existing findings were compiled clearly. However, according to the authors, the findings were not sufficient for a final statement on the successful application of the substance (Watts TL, Coenzyme Q 10 and periodontal treatment: Is there any beneficial effect? Br. Dent. J. 1995; 178 (6): 209 -213).
Die bisher vorgeschlagenen Behandlungs- bzw. Vorbeugemaßnahmen, d. h. orale Verabreichung von Coenzym Q10 oder topische Applikation von reinem Coenzym Q10 werden in der Praxis von den betroffenen Personen nicht konsequent über einen längeren Zeitraum durchgeführt, so dass ein langanhaltender Erfolg ausbleibt.The previously proposed treatment or preventive measures, ie oral administration of coenzyme Q 10 or topical application of pure coenzyme Q 10, are not consistently carried out in practice by the persons concerned over a longer period of time, so that there is no long-term success.
Der im Patentanspruch 1 angegebenen Erfindung liegt das Problem zugrunde, ein Mittel zur Verfügung zu stellen, mit dessen Hilfe es möglich ist, Paradontal-Erkrankungen in der Bevölkerung nachhaltig zurückdrängen zu können.The invention specified in claim 1 is the problem to provide a means by which it is possible is sustainable, paradontal diseases in the population to be able to push back.
Überraschenderweise wurde nun gefunden, dass entzündliche und degenerative Erkrankungen nachhaltig mit einem Zahnpflegemittel, welches eine effektive Menge an Coenzym Q10 enthält, vermieden bzw. zurückgedrängt werden können.Surprisingly, it has now been found that inflammatory and degenerative diseases can be avoided or suppressed sustainably with a dentifrice that contains an effective amount of coenzyme Q 10 .
Gegenstand der Erfindung ist somit ein Zahnpflegemittel enthaltend einen in der Zahnpflege akzeptablen Träger, gegebenenfalls ein oder mehrere Hilfsstoffe und mindestens ein Ubichinon-Derivat zur therapeutischen und/oder präventiven Behandlung entzündlicher und degenerativer Erkrankungen des Zahnfleisches und des Zahnhalteapparates.The invention thus relates to a dentifrice containing one carriers acceptable in dental care, possibly one or more Excipients and at least one ubiquinone derivative for therapeutic and / or preventive treatment of inflammatory and degenerative Diseases of the gums and the tooth structure.
Ein weiterer Gegenstand der Erfindung ist die Verwendung von Ubichinon- Derivaten zur Herstellung eines Zahnpflegemittels zur therapeutischen und/oder präventiven Behandlung entzündlicher und degenerativer Erkrankungen des Zahnfleisches und des Zahnhalteapparates.Another object of the invention is the use of ubiquinone Derivatives for the manufacture of a dental care product for therapeutic and / or preventive treatment of inflammatory and degenerative Diseases of the gums and the tooth structure.
Weiterhin Gegenstand der Erfindung ist eine Methode zur präventiven Behandlung entzündlicher und degenerativer Erkrankungen des Zahnfleisches und des Zahnhalteapparates, wobei ein Zahnpflegemittel enthaltend eine effektive Menge eines Ubichinon-Derivates regelmäßig auf die Zähne und das Zahnfleisch der betroffenen Personen aufgebracht wird.The invention further relates to a method for preventive Treatment of inflammatory and degenerative diseases of the Gums and the tooth retention apparatus, being a dentifrice containing an effective amount of an ubiquinone derivative on a regular basis the teeth and gums of the people affected becomes.
Das Ubichinon-Derivat, vorzugsweise eine Verbindung der Formel I,
insbesondere Coenzym Q10 kann in jeder beliebigen Form zu dem
erfindungsgemäßen Zahnpflegemittel zugesetzt werden, beispielsweise
The ubiquinone derivative, preferably a compound of the formula I, in particular coenzyme Q 10, can be added in any form to the dentifrice according to the invention, for example
- - in reiner Form;- in pure form;
- - in öliger Lösung z. B. in Soja- oder Maisöl,- in oily solution z. B. in soybean or corn oil,
- - in Form verschiedener wässriger Zubereitungen, z. B. in kolloidaler Form, gegebenenfalls in Gegenwart von Tensiden und/oder Stabilisatoren wie es z. B. in der US Patentschrift US 5,785,976 vorgeschlagen wird, deren Offenbarung hierin durch Bezugnahme einbezogen ist; oder- In the form of various aqueous preparations, e.g. B. in colloidal Form, optionally in the presence of surfactants and / or Stabilizers such as. B. in US Pat. No. 5,785,976 the disclosure of which is proposed herein by reference is involved; or
- - in Form von Emulsionen oder Dispersionen in wässrigem Medium.- in the form of emulsions or dispersions in an aqueous medium.
Der Begriff "Zahnpflegemittel" wie er vor- und nachstehend zur Bezeichnung des erfindungsgemäßen Mittels verwendet wird, beinhaltet pasteuse, gel- oder gummiartige Mittel, die mit Hilfe von Bürsten oder durch langanhaltendes Kauen bzw. Lutschen auf die Zähne und das Zahnfleisch aufgebracht werden können, er umfasst somit Zahncremes, Zahnpasten, Zahngele, Bonbons mit Zuckerersatz bzw. -austauschstoffen und Zahnpflegekaugummi. Zahnpasten und Zahnpflegekaugummi sind dabei besonders bevorzugt. In bestimmten Fällen kann das erfindungsgemäße Zahnpflegemittel auch in Form von wässrigen oder alkoholisch-wässrigen Zahnspülungen zum Einsatz kommen. Diese umfassen alle Arten von Mundwässern und Mundsprays.The term "dentifrice" as used above and below Name of the agent according to the invention is used pasteuse, gel or gummy means, using brushes or by long-lasting chewing or sucking on the teeth and that Gums can be applied, so it includes toothpastes, Toothpastes, tooth gels, sweets with sugar substitutes or substitutes and dental care chewing gum. Toothpastes and dental care chewing gum are particularly preferred. In certain cases, it can Dentifrices according to the invention also in the form of aqueous or alcoholic-aqueous tooth washes are used. This include all types of mouthwashes and mouth sprays.
Unter dem Begriff "Zahnpflegemittel" wie er vor- und nachstehend zur Bezeichnung des erfindungsgemäßen Mittels verwendet wird, sind weiterhin Paradontal-Therapeutika, Zahnfleischverbände und Prothesen- Haftcremes zu verstehen.Under the term "dentifrice" as above and below for Name of the agent according to the invention is used still periodontal therapeutics, gum bandages and prosthesis Understand adhesive creams.
Die Zusammensetzung des erfindungsgemäßen Zahnpflegemittels, insbesondere der Zahnpasten ist hinsichtlich der Trägermaterialien und Hilfsstoffe an sich unkritisch. In der Regel enthält es reinigende Putzkörper, die in einer wässrigen Phase dispergiert sind, diverse Zusatzstoffe wie Pigmente, Tenside, Verdicker, Konservierungsmittel, karieshemmende Fluorverbindungen, Aroma- und Geschmacksstoffe einschließlich Süßstoffe und Salze, gegebenenfalls Farbstoffe sowie weitere Wirkstoffe.The composition of the dentifrice according to the invention, toothpastes in particular are with regard to the carrier materials and Auxiliaries per se not critical. It usually contains cleansing agents Cleaning bodies that are dispersed in an aqueous phase, various Additives such as pigments, surfactants, thickeners, preservatives, caries-inhibiting fluorine compounds, aroma and flavor substances including sweeteners and salts, optionally colorants and other active ingredients.
Diese Zusatzstoffe sollen üblicherweise eine Mundhygiene bewirken und die Akzeptanz der Zahnpasta, insbesondere bei Kindern oder Haustieren sicherstellen.These additives are usually intended to bring about oral hygiene and acceptance of toothpaste, especially in children or pets to ensure.
Als Putzkörper werden vorzugsweise feinteilige, feste Stoffe, die in Pulverform keine scharfen Kanten, sondern ebene Flächen aufweisen, verwendet, insbesondere Calciumkarbonat, gefällter Kalk, Schlämmkreide, Bimsstein, Calcium- und Magnesiumphosphat, Bariumcarbonat, Glaspulver, Zeolithe, Glimmer, Perlit, Korallenkalk, Talk, Kaolin, Knochensubstanz, Kieselgur, Aluminiumoxid, Siliziumdioxid, Silicagel, Titandioxid, Kaliumhydroxid.Fine-particle, solid substances that are in Powder form no sharp edges, but have flat surfaces, used, especially calcium carbonate, precipitated lime, sludge chalk, Pumice stone, calcium and magnesium phosphate, barium carbonate, Glass powder, zeolites, mica, pearlite, coral lime, talc, kaolin, Bone substance, diatomaceous earth, aluminum oxide, silicon dioxide, silica gel, Titanium dioxide, potassium hydroxide.
Die Wirksamkeit der Putzkörper in wässriger Phase und die Stabilität des Zahnpflegemittels wird durch ein oder mehrere Tenside erhöht. The effectiveness of the cleaning body in the aqueous phase and the stability of the Dental care products are increased by one or more surfactants.
Bevorzugte Tenside sind Natriumlaurylsulfat, Natriumlaurylsarkosinat oder Natriumtaurat.Preferred surfactants are sodium lauryl sulfate, sodium lauryl sarcosinate or Natriumtaurat.
Weiterhin kann die Zahnpasta wie heute allgemein üblich Fluorverbindungen zur Kariesprophylaxe enthalten, die einzusetzenden Fluorverbindungen sind dem Fachmann bekannt, bevorzugt sind Olaflur (N'-Octadecyl-trimethyldiamin-N,N,N'-tris(2-ethanol)-dihydrofluorid), Decaflur (9-Octacecenylamin-hydrofluorid), Natriumfluorid und Natriummonofluorphosphat. Weiterhin kann zur Erhöhung der Paradontose-Prophylaxe Vitamin A zugesetzt werden. Weiterhin übliche Zusätze sind Glycerin, Sorbit und andere Zucker, z. B. Disaccharide und/oder Zuckeralkohole sowie Polyethylenglykol, Polypropylenglykol, PEG-40, Castor Öl, echte, natürliche oder synthetische Süßstoffe wie Saccharin oder süßende Peptide; Binde- und Verdickungsmittel, z. B. Celluloseester und -ether wie Carboxymethylcellulosen oder Hydroxyethylcellulosen; Konservierungsmittel wie Hydroxybenzoate, Ascorbinsäure oder Zitronensäure, Farbstoffe, Aromastoffe wie Pfefferminzöl oder Fleischaroma für den Einsatz bei Haustieren, insbesondere bei Hunden und Katzen, Pigmente.Furthermore, toothpaste can be used as is common today Fluorine compounds for caries prevention contain the ones to be used Fluorine compounds are known to the person skilled in the art, olaflur is preferred (N'-octadecyl-trimethyldiamin-N, N, N'-tris (2-ethanol) -dihydrofluorid) Decaflur (9-octacecenylamine hydrofluoride), sodium fluoride and Sodium monofluorophosphate. Furthermore, to increase the Periodontal prophylaxis vitamin A can be added. Still common Additives are glycerin, sorbitol and other sugars, e.g. B. Disaccharides and / or sugar alcohols as well as polyethylene glycol, polypropylene glycol, PEG-40, Castor oil, real, natural or synthetic sweeteners like Saccharin or sweetening peptides; Binding and thickening agents, e.g. B. Cellulose esters and ethers such as carboxymethyl celluloses or hydroxyethylcelluloses; Preservatives such as hydroxybenzoates, Ascorbic acid or citric acid, colorants, flavorings such as Peppermint oil or meat flavoring for use with pets, especially in dogs and cats, pigments.
Vorteilhafte Ausgestaltungen des erfindungsgemäßen Mittels sind solche Zahnpflegemittel mit einem Gehalt von 0,1 bis 10,0 Gew.-%, vorzugsweise 0,3 bis 3,0 Gew.-%, insbesondere etwa 0,5 bis 2,5 Gew.-% an mindestens einem Ubichinon-Derivat der Formel (I), insbesondere Coenzym Q10.Advantageous embodiments of the agent according to the invention are dental care agents with a content of 0.1 to 10.0% by weight, preferably 0.3 to 3.0% by weight, in particular approximately 0.5 to 2.5% by weight. on at least one ubiquinone derivative of the formula (I), in particular coenzyme Q 10 .
In einer besonders bevorzugten Ausführungsform weist das
erfindungsgemäße Zahnpflegemittel in Form einer Zahnpasta folgende
Zusammensetzung auf:
In a particularly preferred embodiment, the dentifrice according to the invention in the form of a toothpaste has the following composition:
Auch das erfindungsgemäße Zahnpflegekaugummi ist hinsichtlich der Trägermaterialien und Hilfsstoffe an sich unkritisch. In der Regel enthält es eine wasserunlösliche "Gumbase" und einen wasserlöslichen Anteil, welcher Geschmacksstoffe enthält. Der wasserlösliche Anteil löst sich während der Kauens auf und die "Gumbase" verbleibt während des Kauvorgangs im Mund.The dental care chewing gum according to the invention is also regarding the Carrier materials and auxiliary materials are not critical per se. As a rule, it contains a water-insoluble "gumbase" and a water-soluble portion, which contains flavors. The water-soluble part dissolves during chewing and the "gumbase" remains during the Chewing in the mouth.
Die "Gumbase" kann Elastomere, Harze, Fette, Öle, Weichmacher, Wachse und anorganische Füllmaterialien enthalten. Die Elastomere können synthetische Elastomere enthalten wie zum Beispiel Polyisobutylen, Isobutylen-Isopren-Copolymere, Styrol-Butadien- Copolymere, Polyvinylacetat, Polyisopren, Polyethylen, Vinylacetat- Vinyllaurat-Copolymer und Kombinationen daraus. Natürliche elastomere umfassen natürliches Gummi. In der Regel enthält der Kaugummi 5 bis 95 Gew.-%, vorzugsweise 10 bis 50 Gew.-%, insbesondere 20 bis 35 Gew.-% "Gumbase". The "gumbase" can contain elastomers, resins, fats, oils, plasticizers, Contain waxes and inorganic fillers. The elastomers can contain synthetic elastomers such as Polyisobutylene, isobutylene-isoprene copolymers, styrene-butadiene Copolymers, polyvinyl acetate, polyisoprene, polyethylene, vinyl acetate Vinyl laurate copolymer and combinations thereof. Natural elastomers include natural rubber. As a rule, the chewing gum contains 5 to 95% by weight, preferably 10 to 50% by weight, in particular 20 to 35% by weight "Gum base".
Der wasserlösliche Anteil umfasst Süßstoffe, Geschmacksstoffe, Emulgatoren, Farbstoffe, Säuerungsmittel, Füllstoffe, Antioxidantien und andere Komponenten, die dem Kaugummi die gewünschten Attribute verleihen.The water-soluble portion includes sweeteners, flavors, Emulsifiers, dyes, acidulants, fillers, antioxidants and other components that give the chewing gum the attributes you want to lend.
Die Süßstoffe umfassen Zucker und Zuckerfreie Komponenten. Geeignete Zucker sind Sucrose, Dextrose, Maltose, Dextrin, Invertzucker, Fruktose, Levulose, Galactose. Sorbit wird vorzugsweise als Zucker-freier Süßstoff eingesetzt; daneben können aber auch Mannit, Xylit und andere hydrierte Stärkehydrolysate verwendet werden. Der erfindungsgemäße Kaugummi enthält in der Regel 5 bis 95 Gew.-%, vorzugsweise 20 bis 80 Gew.-%, insbesondere 30 bis 60 Gew.-% eines oder mehrerer dieser Süßstoffe.The sweeteners include sugar and sugar-free components. Suitable sugars are sucrose, dextrose, maltose, dextrin, invert sugar, Fructose, levulose, galactose. Sorbitol is preferably considered sugar-free Sweetener used; In addition, mannitol, xylitol and others can also be used hydrogenated starch hydrolysates can be used. The invention Chewing gum usually contains 5 to 95% by weight, preferably 20 to 80 wt .-%, in particular 30 to 60 wt .-% of one or more of these Sweeteners.
Zusätzlich können künstliche Süßverstärker wie zum Beispiel Sucralose, Aspartam, Salze von Acesulfam, Alitam, Saccharin, Cyclamat und Gycyrrhizin und dergleichen zugesetzt werden. Der erfindungsgemäße Kaugummi enthält in der Regel 0,02 bis 8 Gew.-% eines oder mehrerer dieser Süßverstärker.In addition, artificial sweeteners such as sucralose, Aspartame, salts of acesulfame, alitame, saccharin, cyclamate and Gycyrrhizin and the like can be added. The invention Chewing gum usually contains 0.02 to 8% by weight of one or more this sweet booster.
Als Geschmacksstoffe kommen zum Beispiel Pfefferminzöl, Spearmint-Öl, Minzöl, Anisöl und Zimt in Betracht.For example, peppermint oil, spearmint oil, Mint oil, anise oil and cinnamon come into consideration.
In einer besonders bevorzugten Ausführungsform weist das
erfindungsgemäße Zahnpflegemittel in Form eines Zahnpflegekaugummis
folgende Zusammensetzung auf:
In a particularly preferred embodiment, the dental care product according to the invention in the form of a dental care chewing gum has the following composition:
Das erfindungsgemäße Zahnpflegemittel wird üblicherweise regelmäßig, vorzugsweise zwei- bis viermal täglich, insbesondere morgens und abends sowie nach den Mahlzeiten mit Hilfe einer Zahnbürste oder auf direktem Wege zum Beispiel durch Kauen eines erfindungsgemäßen Zahnpflegekaugummis oder Lutschen eines zuckerfreien Bonbons auf die Zähne und/oder das Zahnfleisch aufgetragen und gegebenenfalls einmassiert. In der Regel wird bei jeder Anwendung 1 bis 100 mg, vorzugsweise 3 bis 40 mg Ubichinon-Derivat aufgetragen.The dentifrice according to the invention is usually regular, preferably two to four times a day, especially in the morning and in the evening as well as after meals with the help of a toothbrush or directly Ways, for example, by chewing an inventive one Dental hygiene chewing gum or sucking a sugar-free candy on the Teeth and / or gums are applied and if necessary massaged. As a rule, 1 to 100 mg, preferably 3 to 40 mg of ubiquinone derivative applied.
Das erfindungsgemäße Zahnpflegemittel kann im Rahmen der nachfolgenden Patentansprüche weiter verändert und vervollkommnet werden. So ist es zum Beispiel möglich, Vitamin A zur Erhöhung der Paradontose-Prophylaxe hinzuzufügen. Dabei kann bei bestimmten Patientengruppen zwischen Coenzym Q10 und Vitamin A ein synergistischer Effekt auftreten.The dentifrice according to the invention can be further modified and perfected within the scope of the following claims. For example, it is possible to add vitamin A to increase periodontal prophylaxis. In certain patient groups, a synergistic effect can occur between coenzyme Q 10 and vitamin A.
Claims (14)
- - in reiner Form;
- - in öliger Lösung z. B. in Soja- oder Maisöl,
- - in Form einer wässrigen, kolloidalen Zubereitung, oder
- - in Form einer Suspension oder Emulsion in wässrigem Medium
- - in pure form;
- - in oily solution z. B. in soybean or corn oil,
- - in the form of an aqueous, colloidal preparation, or
- - in the form of a suspension or emulsion in an aqueous medium
10. Toothpaste according to claim 6 or 9, characterized in that it has the following composition:
12. Dental care chewing gum according to claim 6, 8 or 11, characterized in that it has the following composition:
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2000165413 DE10065413A1 (en) | 2000-12-31 | 2000-12-31 | Dentifrice |
| PCT/EP2001/015172 WO2002053148A1 (en) | 2000-12-31 | 2001-12-20 | Ubiquinone derivatives containing dental care agents |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2000165413 DE10065413A1 (en) | 2000-12-31 | 2000-12-31 | Dentifrice |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE10065413A1 true DE10065413A1 (en) | 2002-12-12 |
Family
ID=7669256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2000165413 Withdrawn DE10065413A1 (en) | 2000-12-31 | 2000-12-31 | Dentifrice |
Country Status (2)
| Country | Link |
|---|---|
| DE (1) | DE10065413A1 (en) |
| WO (1) | WO2002053148A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312173A1 (en) * | 2003-03-19 | 2004-09-30 | Ingo Hornung | Chewing gum is provided with active ingredients intended to produce beneficial effects on the mouth cavity, pharynx, esophagus, stomach and digestive trac |
| DE102010017183A1 (en) | 2009-06-02 | 2010-12-30 | Sven Hurtig | Dentifrice |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0126085D0 (en) * | 2001-10-31 | 2001-12-19 | Smithkline Beecham Plc | Composition |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61286314A (en) * | 1985-06-11 | 1986-12-16 | Shiseido Co Ltd | Composition for oral cavity |
| AU2889292A (en) * | 1992-09-16 | 1994-04-12 | Institut Fur Sozial-Medizinische Forschung | A chewable composition comprising coenzyme q 10 |
| US5925335A (en) * | 1997-06-12 | 1999-07-20 | C.S. Bioscience Inc. | Dental formulation |
| US5908613A (en) * | 1997-09-08 | 1999-06-01 | Bozzacco; Craig | Composition for the treatment and prevention of periodontal disease |
| DE19802050A1 (en) * | 1998-01-21 | 1999-07-22 | Labtec Gmbh | Peridontal treatment composition providing local oral release of coenzyme Q10 |
| US6200550B1 (en) * | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
-
2000
- 2000-12-31 DE DE2000165413 patent/DE10065413A1/en not_active Withdrawn
-
2001
- 2001-12-20 WO PCT/EP2001/015172 patent/WO2002053148A1/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| JP 61286314 A. Pat. Abstr. of Jp., * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10312173A1 (en) * | 2003-03-19 | 2004-09-30 | Ingo Hornung | Chewing gum is provided with active ingredients intended to produce beneficial effects on the mouth cavity, pharynx, esophagus, stomach and digestive trac |
| DE102010017183A1 (en) | 2009-06-02 | 2010-12-30 | Sven Hurtig | Dentifrice |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002053148A1 (en) | 2002-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4111916B2 (en) | Composition for alleviating xerostomia and treating related diseases | |
| RU2385709C2 (en) | Oral care composition for prevention of dental deposit containing magnolia extract | |
| US20070098650A1 (en) | Dental formulation | |
| EP4044996B1 (en) | Oral care composition | |
| KR20200012181A (en) | Toothpaste composition comprising herbal extract mixture as effective component | |
| KR20180081032A (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
| AU2011382468A1 (en) | Oral care composition comprising isobutyl magnolol | |
| KR20120117387A (en) | Oral care preventive and prophylactic composition | |
| KR20080079776A (en) | Composition of toothpaste which contains flower fragments | |
| KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
| JPH04182419A (en) | Composition for oral cavity use | |
| KR101881636B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
| DE10065413A1 (en) | Dentifrice | |
| JP2015500233A (en) | Oral care composition | |
| EP4044995B1 (en) | Oral care composition | |
| DE68914451T2 (en) | ORAL SUPPLIES. | |
| KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
| KR20170103494A (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
| KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
| WO2006110183A2 (en) | Dental formulation | |
| EP4389228A1 (en) | Oral care composition containing cellulosic polymers | |
| KR102562829B1 (en) | Composition for prevention or treatment of oral disease comprising Alpinia officinarum Extract | |
| KR20220080874A (en) | Oral composition | |
| KR20170103517A (en) | Composition for prevention or treatment of oral disease comprising Prunus yedoensis Matsumura extract | |
| KR20170142975A (en) | Composition for prevention or treatment of oral disease comprising Leonurus sibiricus extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| 8139 | Disposal/non-payment of the annual fee |